Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Finished Goods (2019 - 2022)

Marimed has reported Finished Goods over the past 4 years, most recently at $5.3 million for Q1 2022.

  • Quarterly Finished Goods rose 70.88% to $5.3 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Mar 2022, up 70.88% year-over-year, with the annual reading at $3.8 million for FY2021, 35.17% up from the prior year.
  • Finished Goods was $5.3 million for Q1 2022 at Marimed, up from $3.8 million in the prior quarter.
  • Over five years, Finished Goods peaked at $5.8 million in Q3 2021 and troughed at $518166.0 in Q4 2019.
  • The 4-year median for Finished Goods is $3.8 million (2021), against an average of $3.8 million.
  • Year-over-year, Finished Goods soared 446.82% in 2020 and then surged 35.17% in 2021.
  • A 4-year view of Finished Goods shows it stood at $518166.0 in 2019, then soared by 446.82% to $2.8 million in 2020, then surged by 35.17% to $3.8 million in 2021, then surged by 37.47% to $5.3 million in 2022.
  • Per Business Quant, the three most recent readings for MRMD's Finished Goods are $5.3 million (Q1 2022), $3.8 million (Q4 2021), and $5.8 million (Q3 2021).